No Data
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study Was Officially Released at TCT 2024
Genex Technology-B(09877.HK): LuX-Valve Plus TRAVEL II one-year clinical follow-up results will be released at the 2024 Washington conference of the American College of Cardiology.
GloryOct31NewsFlash HealthTech-B (09877.HK) announced that recently, the one-year clinical follow-up results of the LuX-Valve Plus vascular tricuspid valve intervention replacement system multicenter clinical trial (TRAVEL II) were unveiled at the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) in the USA. TRAVEL II is mainly used to evaluate the long-term safety and effectiveness of LuX-Valve Plus in patients with severe tricuspid valve regurgitation. The TRAVEL II clinical trial included a total of 96 patients from 15 centers in China.
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Zhito Hong Kong shareholder equity disclosure | October 28th
Hong Kong Shareholder Equity Disclosure | October 28th
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion in 4 years.
JENSCARE-B: 2024 Interim Report
Pleasing Signs As A Number Of Insiders Buy Jenscare Scientific Stock
No Data
